Hinova's Heterocyclic AR Degrader EP4378936A1

Fri, 17 Apr 2026 23:23:51 +0000
Intellectual Property

The European Patent Office published patent application EP4378936A1, filed by Hinova Pharmaceuticals Inc., covering bifunctional chimeric heterocyclic compounds designed to degrade androgen receptors for therapeutic use. The patent designates 31 EPO member states and classifies under C07D (heterocyclic compounds), A61K (pharmaceutical preparations), and A61P 35/00 (anticancer agents). The filing names 17 inventors and represents a pharmaceutical manufacturer's IP protection strategy for a targeted cancer therapy compound.